Infectious Disease · AntiviralRegulatory Approvalcommercialmid-term

Aurobindo Pharma's Aciclovir ANDA216331 Receives AP Status from FDA

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Aurobindo Pharma25 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/9/2026, 12:30:29 PM

Assessment confidence: 65% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's AP status for Aurobindo Pharma's Aciclovir signals a potential shift in the competitive landscape of the antiviral market. This could lead to pricing pressures and necessitate strategic adjustments for existing players in the Aciclovir segment. Regulatory context from FDA (FDA AP — ACYCLOVIR (SUPPL)) supports the near-term read. Assessment grounded in 22 ranked evidence items (9 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of Aurobindo's entry on market dynamics and pricing strategies for existing Aciclovir products. The strongest clinical anchor is A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (ClinicalTrials.gov), sponsor/company relevance (roche). In Infectious Disease · Antiviral, 6 regulatory and 4 competitive items passed relevance filtering for Aurobindo Pharma.

Competitive Pressure

The most relevant competitive pressure comes from Roche's Elecsys IGRA TB Test Receives CE Mark for Tuberculosis Detection (Humanexa Signals) — mechanism alignment (io ); sponsor/company relevance (roche). Secondary pressure from FDA Grants Emergency Use Authorization for Remdesivir in Severe COVID-19 Cases. This AP status indicates that Aurobindo is positioned to enter the market for Aciclovir, potentially increasing competition in the antiviral segment.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — ACYCLOVIR (SUPPL) (FDA). Entity match (aurobindo pharma); Regulatory pathway relevance (nda). While the AP status indicates progress, the final approval and market entry timelines remain critical for assessing compliance and regulatory implications.

Key Risks

Elevated medium regulatory exposure for Aurobindo Pharma could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Aurobindo's entry may disrupt current market dynamics, impacting revenue and market share for existing Aciclovir products as competition intensifies.
Portfolio teams should assess the impact of Aurobindo's entry on market dynamics and pricing strategies for existing Aciclovir products.

What Would Change This Assessment

This becomes more urgent if Monitor the final approval status and any subsequent market entry timelines for Aurobindo's Aciclovir.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — ACYCLOVIR (SUPPL)
FDAhigh relevance
Entity match (aurobindo pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ALFUZOSIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (aurobindo pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — FINASTERIDE (SUPPL)
FDAhigh relevance
Entity match (aurobindo pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ICOSAPENT ETHYL (ORIG)
FDAhigh relevance
Entity match (aurobindo pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related Disorders
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Remote Dynamic Cycling for the Customized Off-site Rehab in Parkinson's Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Improving Outcomes and Reducing Disparities for Patients With Inflammatory Bowel Disease Through Epidemiology and Enhanced Disease Management
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Influence of Maternal Age, Employment Status, and Parenthood Status on Children's Cognitive Development
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's Elecsys IGRA TB Test Receives CE Mark for Tuberculosis Detection
Humanexa Signalshigh relevance
Mechanism alignment (IO ); Sponsor/company relevance (Roche)
FDA Grants Emergency Use Authorization for Remdesivir in Severe COVID-19 Cases
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves Veklury as First Treatment for COVID-19
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Accepts Supplemental NDA for NUPLAZID by ACADIA PHARMS
Humanexa Signalsmedium relevance
Moderate corpus alignment

RNA polymerase II phosphorylation dynamics: from molecular mechanisms to human disease.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Purinergic activity of circulating extracellular vesicles associates with disease progression in melanoma.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Insect-based models in pharmaceutical ecotoxicology: a bibliometric and narrative review.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Lavandula angustifolia as a dual pharmacological system: from essential oil to polyphenol-rich biomass.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Aurobindo Pharma
Aciclovir

Commercial impact

medium

Aurobindo's entry may disrupt current market dynamics, impacting revenue and market share for existing Aciclovir products as competition intensifies.

Regulatory impact

medium

While the AP status indicates progress, the final approval and market entry timelines remain critical for assessing compliance and regulatory implications.

What to watch

Monitor the final approval status and any subsequent market entry timelines for Aurobindo's Aciclovir.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.